Company intelligence / Profile preview

Picterus

Trondheim, Trøndelag, Norwaypicterus.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Clinical studies have shown that the Picterus Jaundice Pro app provides a significant and high positive correlation with total serum bilirubin measurements in newborns. No systematic overestimation or underestimation was observed compared to standard methods. The tool has been validated in clinical settings and received CE certification as a class IIa medical device for neonatal jaundice screening. Exclusion criteria apply for certain skin tones due to current validation limits.

Therapeutic areas: Gastroenterology
Modalities: DeviceDigital health platformmHealth application
Industry: Digital Health Medical Devices

Partnerships

European Union Horizon 2020 research program funding partner

Beyond the preview

Go deeper on Picterus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picterus.

Explore the full profile